If you arent, it wont matter
Some people switch, often due to tolerability or response
Key Takeaways: The 2025 Launch Pipeline The $29 billion aggregate forecast reflects a shift in the commercial center of gravity in pharma away from blockbuster mass-market drugs (where pricing pressure from PBMs, IRA negotiation, and international reference pricing compresses net revenues) toward rare and specialty biologics and first-in-class small molecules where the IP estate is durable, the payer negotiating position is stronger, and the per-patient economics justify the infrastructure investment
doi:10.3233/JAD-130584 190
Distinct mTORC1 pathways for transcription and cleavage of SREBP-1c
Sources: 1 Medication Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss FDA 2 GLP-1 agonists: Diabetes drugs and weight loss Mayo Clinic 3 GLP-1 Drugs Comparison GoodRx FDA Drug Release Info: Adlyxin: FDA approves Adlyxin to treat type 2 diabetes | FDA Byetta: Drug Approval Package: Byetta (Exenatide) NDA #021773 (fda.gov) Mounjaro: FDA Approves Novel, Dual-Targeted Treatment for Type 2 Diabetes | FDA Ozempic: FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014 FDA Rybelsus: FDA approves first oral GLP-1 treatment for type 2 diabetes FDA Saxenda: FDA approves weight management drug for patients aged 12 and older | FDA Trulicity: FDA Drug Approval Package Victoza: FDA Drug Apprival Package Wegovy: FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014
